

This policy applies to the following:

✓	Standard Opt-in	✓	ACSF	✓	VF	✓	Marketplace
	Standard Opt-in NTMB	✓	PDPD		MMT		Medical Benefit
	Standard Opt-out		Generics First				NTMB

Reference #
2349-D

## EXCEPTIONS CRITERIA

### HEPATITIS C DIRECT-ACTING ANTIVIRALS (DAA) PREFERRED PRODUCTS: EPCLUSA, HARVONI, VOSEVI

#### POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

#### I. PLAN DESIGN SUMMARY

This program applies to the hepatitis C direct-acting antiviral agents specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to the treatment regimen with a targeted product. Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

**Table. Hepatitis C Direct-Acting Antivirals**

Genotype	Preferred Products	Targeted Products^
1, 4, 5, 6	Epclusa Harvoni Vosevi*	Daklinza Mavyret Olysio Sovaldi Technivie Viekira Pak/XR Zepatier
2, 3	Epclusa Vosevi*	

^ if applicable for specific genotype

\* Vosevi is specifically preferred for those who failed prior treatment with an HCV NS5A inhibitor-containing regimen.

This policy applies to the following:

✓	Standard Opt-in	✓	ACSF	✓	VF	✓	Marketplace
	Standard Opt-in NTMB	✓	PDPD		MMT		Medical Benefit
	Standard Opt-out		Generics First				NTMB

Reference #
2349-D

## II. EXCEPTION CRITERIA

Coverage for a targeted product is provided when any of the following criteria is met:

- A. Member is currently receiving treatment with a targeted product.
- B. For Mavyret, Zepatier, Viekira Pak/XR, the member has documented end-stage renal disease (ESRD) or severe renal impairment (estimated glomerular filtration rate [eGFR] of less than 30 mL/min/1.73m<sup>2</sup>).

## REFERENCES

1. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2017.
2. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2017.
3. Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; February 2017.
4. Olysio [package insert]. Titusville, NJ: Janssen Products, LP; May 2017.
5. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2017.
6. Technivie [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
7. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
8. Viekira XR [package insert]. North Chicago, IL: AbbVie Inc.; March 2017.
9. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February 2017.
10. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; July 2017.
11. Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; August 2017.